Equity (Details) $ / shares in Units, dose in Millions, $ in Millions						1 Months Ended	4 Months Ended	12 Months Ended
	Apr. 27, 2021 USD ($)	Apr. 23, 2021 $ / shares shares	Mar. 01, 2021 dose $ / shares shares	Feb. 10, 2021 USD ($)	Feb. 07, 2021 $ / shares shares	Jun. 30, 2019 USD ($) shares	Aug. 31, 2020 at-the-marketOffering	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Apr. 30, 2021 shares	Apr. 29, 2021 shares	Dec. 31, 2019 USD ($)
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in USD per share) | $ / shares								$ 0.01	$ 0.01
Common stock, shares authorized (in shares) | shares								295,000,000	200,000,000	295,000,000	200,000,000
Number of At-the-Market offerings | at-the-marketOffering							3
Senior Secured Convertible Notes
Subsidiary, Sale of Stock [Line Items]
Debt instrument, face amount | $												$ 5.3
Series B Convertible Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Preferred stock, outstanding | $								$ 5.0
Series B Convertible Preferred Stock | Level 3 | Measurement Input, Discount Rate
Subsidiary, Sale of Stock [Line Items]
Preferred stock, measurement input								0.15
COVAXIN Preferred Stock Purchase Agreement | Series B Convertible Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Number of shares agreed to issue and sell | shares			100,000
Convertible preferred stock, par value (in USD per share) | $ / shares			$ 0.01
Price per share ( in USD per share) | $ / shares			$ 109.60
Shares issued upon conversion (in shares) | shares			10
Supply agreement, number of doses | dose			10.0
Registered Direct Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold | shares		10,000,000			3,000,000
Price per share (in USD per share) | $ / shares		$ 10.00			$ 7.65
Proceeds from sale of stock | $	$ 93.4			$ 21.2
Commissions, fees and expenses | $	$ 6.6			$ 1.7
ATMs
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold | shares								1,000,000	108,100,000
Proceeds from sale of stock | $								$ 4.8	$ 36.3
Commissions, fees and expenses | $								$ 0.1	$ 1.5
Financing SPA
Subsidiary, Sale of Stock [Line Items]
Number of converted initial shares, agreed to be issued (in shares) | shares						2,200,000
Number of converted additional shares in the form of escrow agreed to issue immediately prior to the merger (in shares) | shares						2,200,000
Sale of stock, consideration received | $						$ 25.0